Genmab A/S IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Genmab A/S | GMAB - NASDAQ |
$18.11-$18.11 | $17.75 | $18.25 | 28.5 million ADSs | 7/18/2019 |
| BofA Merrill Lynch, Morgan Stanley, Jefferies, Guggenheim Securities, RBC Capital | ||||||
Co-Manager(s): Danske Markets, HC Wainwright, Kempen | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-05-28 Terms Added 2019-07-09 | ||||||
Genmab A/S Quote & Chart - Click for current quote - GMAB
IPO Boutique aggregates information on public companies and private companies, such as "GMAB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Genmab A/S (adapted from Genmab A/S prospectus):
They are an international biotechnology company specializing in antibody therapeutics for the treatment of cancer and other diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are an international biotechnology company specializing in antibody therapeutics for the treatment of cancer and other diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "GMAB" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.